NCT01226680View on ClinicalTrials.gov

A Study Of Tasocitinib In Dry Eye Subjects

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 1, 2010

Primary Completion Date

October 19, 2012

Study Completion Date

October 19, 2012

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG

Tasocitinib

0.005% QD for 12 weeks

DRUG

Tasocitinib

0.003% QD for 12 weeks

DRUG

vehicle for Tasocitinib

vehicle QD for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY